4-(3-methoxyphenyl)-3-methylbutanoic acid | 54961-40-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-methoxyphenyl)-3-methylbutanoic acid
• CAS: 54961-40-9
• 化学式: C₁₂H₁₆O₃
• 分子量: 208.257
• InChiKey: TZVBTYAWKKAEOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-methoxyphenyl)-3-methylbutanoic acid 在 三氯乙酸酐 作用下， 生成 6-methoxy-3-methyl-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  用三氯乙酸酐进行无溶剂傅-克环化

  摘要：

  摘要 使用 1.1 当量对环境无害的三氯乙酸酐作为唯一的试剂和溶剂，获得了 Friedel-Crafts 环化产物。所得的酮包括苯并噻吩、苯并噻喃、苯并恶英、二苯并噻菌、二苯并恶英和四氢萘酮。

  DOI：

  10.1080/00397910802663394
• 作为产物：
  描述：

  3-甲氧基苯基丙酮 在 水 、 sodium hydride 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 14.25h， 生成 4-(3-methoxyphenyl)-3-methylbutanoic acid
  参考文献：
  名称：

  DIHYDRONAPHTHALENE DERIVATIVES USEFUL IN THE TREATMENT OF S1P5-MEDIATED DISEASES

  摘要：

  公开号：

  EP3228615B1

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2006002185A1

  公开（公告）日：2006-01-05

  The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen receptor modulation.

  本发明涉及一种具有多种治疗用途的新化合物，更具体地说是一种新的萘化合物，特别适用于选择性雌激素受体调节。
• CHEMICAL COMPOUNDS
  申请人：Heyer Dennis

  公开号：US20070276000A1

  公开（公告）日：2007-11-29

  The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen modulation.

  本发明涉及具有各种治疗用途的环烷基亚烯化合物，更具体地涉及新型萘化合物，特别适用于选择性雌激素调节。
• Naphthalene compounds as selective estrogen receptor modulators
  申请人：Glaxo Smith Kline LLC

  公开号：US07649093B2

  公开（公告）日：2010-01-19

  The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen receptor modulation.

  本发明涉及具有多种治疗用途的环烷基亚甲基化合物，更具体地涉及新型萘化合物，特别适用于选择性雌激素受体调节。
• DIHYDRONAPHTHALENE DERIVATIVE
  申请人：ONO Pharmaceutical Co., Ltd.

  公开号：EP3228615A1

  公开（公告）日：2017-10-11

  A compound shown by general formula (I) (in the formula, all of the symbols are as defined in the specification) has selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for the treatment of S1P5-mediated diseases, e.g., neurodegenerative diseases such as schizophrenia.

  通式(I)所示化合物 (式中，所有符号如说明书中所定义）具有选择性 S1P5 受体激动剂活性，这是由于在二氢萘骨架中具有从苯基到环状取代基的连接基；即由于具有通式（I）中 L 所示的一个原子或更少的短连接基，因此可作为治疗 S1P5 介导的疾病（如精神分裂症等神经退行性疾病）的药物。
• Overcoming Undesirable CYP1A2 Inhibition of Pyridylnaphthalene-Type Aldosterone Synthase Inhibitors: Influence of Heteroaryl Derivatization on Potency and Selectivity
  作者：Ralf Heim、Simon Lucas、Cornelia M. Grombein、Christina Ries、Katarzyna E. Schewe、Matthias Negri、Barbara Birk、Rolf W. Hartmann

  DOI：10.1021/jm800377h

  日期：2008.8.1

  Recently, we reported on the development of potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. A major drawback of these nonsteroidal compounds was a strong inhibition of the hepatic drug-metabolizing enzyme CYP1A2. In the present study, we examined the influence of substituents in the heterocycle of lead structures with a naphthalene molecular scaffold to overcome this unwanted side effect. With respect to CYP11B2 inhibition, some substituents induced a dramatic increase in inhibitory potency. The methoxyalkyl derivatives 22 and 26 are the most potent CYP11B2 inhibitors up to now (IC50 = 0.2 nM). Most compounds also clearly discriminated between CYP11B2 and CYP11B1, and the CYP1A2 potency significantly decreased in some cases (e.g., isoquinoline derivative 30 displayed only 6% CYP1A2 inhibition at 2 mu M concentration). Furthermore, isoquinoline derivative 28 proved to be capable of passing the gastrointestinal tract and reached the general circulation after peroral administration to male Wistar rats.